Ocular Therapeutix (NSDQ:OCUL) said today that it plans to launch an underwritten public offering of its common stock to help fund the resubmission of its new drug application for Dextenza, an ocular post-surgical pain-relief implant that was rejected by the FDA last year.
The Bedford, Mass.-based company said it will also offer underwriters a 30-day option to buy an additional 15% of the shares in the public offering on the same terms.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix plans public offering to fund NDA resubmission for Dextenza appeared first on MassDevice.
from MassDevice http://ift.tt/2BtJKxX
Cap comentari:
Publica un comentari a l'entrada